Navigation Links
Key molecule suppresses growth of cancerous liver tumors, Mayo study finds
Date:2/13/2013

ROCHESTER, Minn. -- A molecule already implicated in a number of diverse cellular functions can suppress the growth of tumors in the liver, a Mayo Clinic Cancer Center study has found. Its name is IQGAP1, and when the molecule is active in the cells that surround a tumor cell, this "tumor microenvironment" becomes less hospitable to cancer growth. When the molecule is deficient, cancer thrives.

Results of the study appear in the Journal of Clinical Investigation. The findings give new insight into cancer metastasis, the ability of a tumor to spread from its primary site to distant organs such as the brain, lung or liver. The results also point to new targets for preventing or treating liver metastases, the major cause of death from cancer.

"Tumor cells are intelligent -- they talk to the cells in their surroundings to change the way they behave and make the environment supportive of cancer growth. If we can disrupt the communication between the tumor cells and the tumor microenvironment, we can prevent tumor growth or metastasis in the liver," says senior study author Ningling Kang, Ph.D., a biochemist and molecular biologist at Mayo Clinic.

For certain solid tumors, about 70 to 90 percent of the tumor mass is made up of microenvironment -- a complex mix of noncancerous cells, secreted extracellular matrix proteins, and tumor-promoting signaling molecules. This tumor microenvironment supports tumor growth and drug resistance. Mechanisms regulating the tumor microenvironment are not well understood.

IQGAP1 controls the shape and movement of cells. To study the effects of this molecule on liver metastases, Dr. Kang and her colleagues implanted tumor cells into the livers of mice genetically engineered to lack the molecule.

The implanted tumor cells still had the molecule, but the cells that made up the tumor microenvironment did not. When researchers compared the progression of cancer between mutant and normal mice, they found that mice without the molecule developed more liver metastases. They also followed up these studies in mice by comparing samples of normal and cancerous liver tissues of colorectal cancer patients. They discovered that the levels of IQGAP1 were reduced in the tumor microenvironment of liver metastases than in the normal tissue, suggesting that the tumor somehow communicates with its surroundings to tamp down the activity of this critical molecule.

This communication went both ways. Through a number of basic functional experiments, Dr. Kang and her colleagues showed that IQGAP1 interacts with and suppresses a powerful signaling molecule called TGF-beta receptor that tells normal cells that surround a tumor cell to become tumor-promoting cells.

"We think that tumor cells come into the liver and give orders to the signaling molecules in the surrounding normal cells to reduce the amount of IQGAP1, thereby creating a good tumor microenvironment for themselves," Dr. Kang says. "If we can understand exactly how they do this, then we may be able to uncover new therapeutic targets for liver metastasis."


'/>"/>
Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
2. Beta-catenin molecule is required for tooth root formation
3. Mayo Clinic researchers find new molecule to target in pancreatic cancer treatment
4. CWRU School of Medicine researchers discover new molecule linked to late-stage breast cancer
5. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
6. Looking for the anti-Alzheimers molecule -- A new approach to treating a devastating disease
7. Fat molecule ceramide may factor in muscle loss in older adults
8. New developments reveal a molecule with a promising function in terms of cancer treatment.
9. Measuring molecules with the naked eye
10. Molecule shows effectiveness against drug-resistant myeloma
11. Molecule found that inhibits recovery from stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: